Eloxx Pharmaceuticals (ELOX) Misses Q2 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. HUM
2. SPCX
3. ALHC
4. PEP
5. T
6. TMUS
7. SPY
8. CVS
9. UNH
10. AXP

Go back to Eloxx Pharmaceuticals (ELOX) Misses Q2 EPS by 2c

Eloxx Pharmaceuticals Reports Second Quarter 2022 Financial and Operating Results and Provides Business Update

August 15, 2022 8:00 AM EDT

Topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with ivacaftor expected by the end of the third quarter of 2022

On track to initiate a proof-of-concept clinical trial with ELX-02 in up to eight Alport syndrome patients with nonsense mutations in the second half of 2022

On track to submit an Investigational New Drug (IND) application for the inhaled delivery of ELX-02 in the fourth quarter of 2022

On track to submit IND application for ZKN-013 for the treatment of recessive dystrophic... More